Readystate Asset Management LP Buys New Shares in Vera Therapeutics, Inc. $VERA

Readystate Asset Management LP bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA) in the 2nd quarter, Holdings Channel.com reports. The fund bought 295,114 shares of the company’s stock, valued at approximately $12,663,000.

A number of other institutional investors have also bought and sold shares of the business. Los Angeles Capital Management LLC bought a new stake in Vera Therapeutics during the fourth quarter valued at about $46,000. Aster Capital Management DIFC Ltd bought a new position in shares of Vera Therapeutics in the fourth quarter worth about $71,000. Quantbot Technologies LP purchased a new stake in shares of Vera Therapeutics during the second quarter worth about $51,000. Nykredit A S purchased a new stake in shares of Vera Therapeutics during the second quarter worth about $97,000. Finally, Sandia Investment Management LP purchased a new stake in shares of Vera Therapeutics during the fourth quarter worth about $127,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on VERA shares. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. HC Wainwright cut their price objective on shares of Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Wedbush reissued a “neutral” rating and issued a $34.00 target price on shares of Vera Therapeutics in a report on Monday, August 17th. Jefferies Financial Group restated a “buy” rating and set a $60.00 target price on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, Evercore set a $91.00 price target on shares of Vera Therapeutics in a report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $81.15.

Vera Therapeutics Price Performance

VERA stock opened at $35.89 on Monday. Vera Therapeutics, Inc. has a 52 week low of $21.96 and a 52 week high of $56.05. The firm has a market capitalization of $2.59 billion, a P/E ratio of -6.12 and a beta of 0.96. The company has a fifty day simple moving average of $35.86 and a two-hundred day simple moving average of $37.42. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same quarter in the prior year, the company earned ($1.20) earnings per share. Analysts anticipate that Vera Therapeutics, Inc. will post -6.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the transaction, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,250 shares of company stock valued at $3,307,800 in the last ninety days. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.